Clinical trial
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous…
NCT00096941 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00096941 |
|---|---|
| Title | A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study |
| Official title | An Open-Label, Multicenter Extension Study of Pertuzumab (rhuMAb 2C4) in Subjects Treated With Pertuzumab in a Previous Genentech-Sponsored Phase II Cancer Study |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Solid Cancers |
| Intervention type | Drug |
| Interventions | Pertuzumab |
| Enrollment | 3 |
| Start date | May 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Nov 18, 2004 |
| Last update posted | Jun 11, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: